Clinical trial
Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
NCT03148327 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- October 11, 2017
- Completion date
- April 23, 2026
- Enrollment
- 18 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.